ProfileGDS5678 / 1455513_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 82% 82% 84% 83% 81% 84% 82% 81% 85% 84% 85% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.09984
GSM967853U87-EV human glioblastoma xenograft - Control 26.0217282
GSM967854U87-EV human glioblastoma xenograft - Control 35.8912182
GSM967855U87-EV human glioblastoma xenograft - Control 46.3338784
GSM967856U87-EV human glioblastoma xenograft - Control 56.1627883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6420581
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.049284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8655282
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7436981
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4417485
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1684884
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4923585
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1658284
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0210783